BBT594

• CAT Number: I005303
• CAS Number: 882405-89-2
• Molecular Formula: C28H30F3N7O3
• Molecular Weight: 569.58
• Purity: ≥95%
• Synonyms: BBT594; BBT-594;BBT 594
• Target: RET
• Solubility: DMSO: ≥ 35 mg/mL
• Storage: 0 – 4 under dry condition
• InChI: InChI=1S/C28H30F3N7O3/c1-18(39)34-25-15-26(33-17-32-25)41-22-5-6-24-19(13-22)7-8-38(24)27(40)35-21-4-3-20(23(14-21)28(29,30)31)16-37-11-9-36(2)10-12-37/h3-6,13-15,17H,7-12,16H2,1-2H3,(H,35,40)(H,32,33,34,39)
• InChIKey: VQLNKQZLPGLOSI-UHFFFAOYSA-N
• SMILES: O=C(N1CCC2=C1C=CC(OC3=NC=NC(NC(C)=O)=C3)=C2)NC4=CC=C(CN5CCN(C)CC5)C(C(F)(F)F)=C4

BBT594(CAT: I005303) is indeed a small molecule inhibitor that has been developed as a potential treatment for cancer. It works by inhibiting the activity of multiple receptor tyrosine kinases (RTKs), including RET and JAK2, which are proteins involved in the signaling pathways that control cell growth and division. By blocking these RTKs, BBT594 can inhibit the growth and survival of cancer cells and prevent the formation of new blood vessels that are necessary for tumor growth and metastasis. BBT594 has shown promising results in preclinical studies and has been evaluated in early-stage clinical trials for the treatment of various types of cancer, including non-small cell lung cancer and glioblastoma.

Reference

[1]. Morandi A, et al. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors. Cancer Res. 2013 Jun 15;73(12):3783-95.
[2]. Andreucci E, et al. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts. Oncotarget. 2016 Sep 2. doi: 10.18632/oncotarget.11826. [Epub ahead of print]